dual glp-1/glucagon receptor agonists Trends in the Development of GLP-1 Are peptide conjugates the golden

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection

Eli Lillys first nine months of 2025 underscored the scale of the GLP-1 surge: Mounjaro and Zepbound generated $39.5 billion in revenue and surpasses Mercks Keytruda as the worlds best-selling medicine[5]

Shop GLP3 Retatrutide 40mg, a triple-agonist peptide targeting GLP-1, GIP & Glucagon receptors

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials

Powered by Peptide

87% reduced carb cravings